Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Drug Delivery Systems: Introduction

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Oral Drug Delivery Systems: Continuous-Release Systems

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...

Modified-Release Drug Delivery Systems: Classification

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...

Modified-Release Drug Delivery Systems: Stimuli-Activated

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...

Drug Delivery Systems: Different Types

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Vaccine efficacy against the SARS-CoV-2 Delta variant during a COVID-19 outbreak aboard a military ship.

BMJ military health·2022

Same author

Intercellular ultrafast Ca(2+) wave in vascular smooth muscle cells: numerical and experimental study.

Scientific reports·2016

Same author

Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs.

British journal of cancer·2010

Same author

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days.

British journal of cancer·2006

Same author

Detection and localization of calpain 3-like protease in a neuronal cell line: possible regulation of apoptotic cell death through degradation of nuclear IkappaBalpha.

The international journal of biochemistry & cell biology·2006

Same author

Implication of calpain in neuronal apoptosis. A possible regulation of Alzheimer's disease.

The FEBS journal·2006

Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

Novel drug delivery systems.

¹CRC Centre for Cancer Therapeutics, The Institute Of Cancer Research, Sutton, Surrey, SM2 5NG, UK. floren@icr.ac.uk

Idrugs : the Investigational Drugs Journal

|May 10, 2008

Summary

This summary is machine-generated.

Novel anticancer drug development includes cytokine inducers, cell cycle drugs, monoclonal antibodies, anti-angiogenic compounds, gene therapy, antisense therapy, and vaccines. New guidelines and surrogate endpoints are crucial for preclinical and clinical trials.

More Related Videos

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

Related Experiment Videos

Last Updated: Jul 5, 2026

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models

Published on: August 16, 2010

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

Area of Science:

Oncology
Pharmacology
Biotechnology

Background:

Anticancer drug development is rapidly evolving with novel therapeutic strategies.
Several new therapies, including cytokine inducers, cell cycle modulators, monoclonal antibodies, anti-angiogenic compounds, gene therapy, antisense therapy, and vaccines, are emerging.
These advancements necessitate updated research and clinical trial guidelines.

Purpose of the Study:

To review novel approaches in anticancer drug development.
To highlight the need for new guidelines in preclinical and clinical research for these therapies.
To emphasize the challenge of identifying surrogate endpoints for efficacy.

Main Methods:

Literature review of recent advancements in anticancer drug development.
Analysis of emerging therapeutic modalities and their clinical translation.
Discussion of the implications for preclinical and clinical trial design.

Main Results:

A diverse range of novel anticancer therapies have been developed and some are entering clinical use.
These include immunotherapies, targeted therapies, and genetic/nucleic acid-based treatments.
The complexity of these new agents poses challenges for traditional research and trial methodologies.

Conclusions:

The landscape of cancer treatment is being transformed by innovative drug development.
Establishing clear guidelines for preclinical research and early-phase clinical trials (Phase I and II) is essential.
The identification and validation of surrogate endpoints are critical for efficient evaluation of novel anticancer agents.